-
-
-
-
-
-
-
Kala Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
-
-
-
-
-
-
-
Kala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS™ for Dry Eye Disease
-
-
-
-
-
-
-
Kala Pharmaceuticals (KALA) Receives FDA CRL for KPI-121 0.25% NDA and Plans to Respond with Data From STRIDE 3 Trial
-
-
-
-
-
-
-
Kala Pharmaceuticals (KALA) Reports In-Line Q1 EPS, Revenues Beat
-
-
-
-
-
-
-
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
-
-
-
-
-
-
-
Kala Pharmaceuticals (KALA) Announces NDA for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by FDA
-
-
-
-
-
-
-
Kala Pharmaceuticals (KALA) Provides Update to KPI-121 0.25% Development Plan, Sees NDA in H2
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

